Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 763

1.

Survival by Histologic Subtype of Malignant Pleural Mesothelioma and the Impact of Surgical Resection on Overall Survival.

Verma V, Ahern CA, Berlind CG, Lindsay WD, Shabason J, Sharma S, Culligan MJ, Grover S, Friedberg JS, Simone CB 2nd.

Clin Lung Cancer. 2018 Aug 29. pii: S1525-7304(18)30201-8. doi: 10.1016/j.cllc.2018.08.007. [Epub ahead of print]

PMID:
30224273
2.

Patterns of Care and Outcomes of Elderly Esophageal Cancer Patients Not Meeting Age-based Criteria of the CROSS Trial.

Verma V, Haque W, Zheng D, Osayande F, Lin C.

Am J Clin Oncol. 2018 Sep 13. doi: 10.1097/COC.0000000000000481. [Epub ahead of print]

PMID:
30216194
3.

Postoperative chemoradiotherapy versus radiotherapy alone for elderly cervical cancer patients with positive margins, lymph nodes, or parametrial invasion.

Cushman TR, Haque W, Menon H, Rusthoven CG, Butler EB, Teh BS, Verma V.

J Gynecol Oncol. 2018 Nov;29(6):e97. doi: 10.3802/jgo.2018.29.e97.

4.

Association of Vitamin D and Parathyroid Hormone with Insulin Sensitivity, Beta Cell Function and Gestational Diabetes in Pregnancy: A Cross-Sectional, Observational Study.

Nachankar A, Kotwal N, Upreti V, Verma V, Hari Kumar KVS.

Diabetes Ther. 2018 Sep 11. doi: 10.1007/s13300-018-0508-z. [Epub ahead of print]

PMID:
30206904
5.

Retrospective Evaluation of Patients Who Leave against Medical Advice in a Tertiary Teaching Care Institute.

Gautam N, Sharma JP, Sharma A, Verma V, Arora P, Gautam PL.

Indian J Crit Care Med. 2018 Aug;22(8):591-596. doi: 10.4103/ijccm.IJCCM_375_17.

6.

Flexible agar-sericin hydrogel film dressing for chronic wounds.

Tyeb S, Kumar N, Kumar A, Verma V.

Carbohydr Polym. 2018 Nov 15;200:572-582. doi: 10.1016/j.carbpol.2018.08.030. Epub 2018 Aug 9.

PMID:
30177201
7.

Local response and pathologic fractures following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy for spinal metastases - a randomized controlled trial.

Sprave T, Verma V, Förster R, Schlampp I, Hees K, Bruckner T, Bostel T, El Shafie RA, Welzel T, Nicolay NH, Debus J, Rief H.

BMC Cancer. 2018 Aug 31;18(1):859. doi: 10.1186/s12885-018-4777-8.

8.

Trends and disparities in the utilization of hypofractionated neoadjuvant radiation therapy for rectal cancer in the United States.

Haque W, Verma V, Butler EB, Teh BS.

J Gastrointest Oncol. 2018 Aug;9(4):601-609. doi: 10.21037/jgo.2018.05.08.

9.

Integrated Telehealth and Telecare for Monitoring Frail Elderly with Chronic Disease.

Gokalp H, de Folter J, Verma V, Fursse J, Jones R, Clarke M.

Telemed J E Health. 2018 Aug 21. doi: 10.1089/tmj.2017.0322. [Epub ahead of print]

PMID:
30129884
10.

Economic sustainability of immune-checkpoint inhibitors: the looming threat.

Verma V.

Nat Rev Clin Oncol. 2018 Aug 20. doi: 10.1038/s41571-018-0086-z. [Epub ahead of print] No abstract available.

PMID:
30127492
11.

The fundamental problem of confounding by medical operability in retrospective comparisons of surgery versus stereotactic body radiation therapy for early-stage lung cancer.

Verma V, Rusthoven CG.

J Thorac Dis. 2018 Jul;10(Suppl 18):S2176-S2180. doi: 10.21037/jtd.2018.06.99. No abstract available.

12.

Short-wave infrared compressive imaging of single photons.

Gerrits T, Lum DJ, Verma V, Howell J, Mirin RP, Nam SW.

Opt Express. 2018 Jun 11;26(12):15519-15527. doi: 10.1364/OE.26.015519.

PMID:
30114811
13.

Ultra-sensitive mid-infrared emission spectrometer with sub-ns temporal resolution.

Chen L, Schwarzer D, Lau JA, Verma VB, Stevens MJ, Marsili F, Mirin RP, Nam SW, Wodtke AM.

Opt Express. 2018 Jun 11;26(12):14859-14868. doi: 10.1364/OE.26.014859.

PMID:
30114791
14.

Impact of Enlarged Nonhypermetabolic Lymph Nodes on Outcomes After Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer.

Verma V, Schonewolf CA, Cushman TR, Post CM, Doms A, Berman AT, DeVries M, Katz SI, Simone CB 2nd.

Clin Lung Cancer. 2018 Jul 25. pii: S1525-7304(18)30172-4. doi: 10.1016/j.cllc.2018.07.005. [Epub ahead of print]

PMID:
30111509
15.

Disrupting Gram-negative bacterial outer membrane biosynthesis through inhibition of the lipopolysaccharide transporter MsbA.

Alexander MK, Miu A, Oh A, Reichelt M, Ho H, Chalouni C, Labadie S, Wang L, Liang J, Nickerson NN, Hu H, Yu L, Du M, Yan D, Park S, Kim J, Xu M, Sellers BD, Purkey HE, Skelton N, Koehler MFT, Payandeh J, Verma V, Xu Y, Koth CM, Nishiyama M.

Antimicrob Agents Chemother. 2018 Aug 13. pii: AAC.01142-18. doi: 10.1128/AAC.01142-18. [Epub ahead of print]

PMID:
30104274
16.

Qualitative ultrasonography for bone health: Are we there yet?

Verma V, Menon AS.

Med J Armed Forces India. 2018 Jul;74(3):309-310. doi: 10.1016/j.mjafi.2018.05.002. Epub 2018 Jul 3. No abstract available.

PMID:
30093783
17.

Handlebar Hernia with Triple Herniation and Perforation: A Case Report and Literature Review.

Shukla A, Verma V, Lal Kapoor K, Gupta B, Chaudhry R.

Bull Emerg Trauma. 2018 Jul;6(3):257-261. doi: 10.29252/beat-060313.

18.

Mangiferin attenuates cisplatin-induced acute kidney injury in rats mediating modulation of MAPK pathway.

Sahu AK, Verma VK, Mutneja E, Malik S, Nag TC, Dinda AK, Arya DS, Bhatia J.

Mol Cell Biochem. 2018 Aug 6. doi: 10.1007/s11010-018-3420-y. [Epub ahead of print]

PMID:
30083783
19.

Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation.

Fang P, Shiraishi Y, Verma V, Jiang W, Song J, Hobbs BP, Lin SH.

Int J Part Ther. 2018 Winter;4(3):23-32. doi: 10.14338/IJPT-17-00033.1.

20.

Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy.

Cushman TR, Caetano MS, Welsh JW, Verma V.

Immunotherapy. 2018 Aug;10(10):851-0. doi: 10.2217/imt-2018-0019.

PMID:
30073899
21.

Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial.

Sprave T, Verma V, Förster R, Schlampp I, Bruckner T, Bostel T, El Shafie RA, Nicolay NH, Debus J, Rief H.

Anticancer Res. 2018 Aug;38(8):4961-4968. doi: 10.21873/anticanres.12814.

PMID:
30061276
22.

Quality of Life and Radiation-induced Late Toxicity Following Intensity-modulated Versus Three-dimensional Conformal Radiotherapy for Patients with Spinal Bone Metastases: Results of a Randomized Trial.

Sprave T, Verma V, Förster R, Schlampp I, Hees K, Bruckner T, Bostel T, El Shafie R, Nicolay NH, Debus J, Rief H.

Anticancer Res. 2018 Aug;38(8):4953-4960. doi: 10.21873/anticanres.12813.

PMID:
30061275
23.

Cost-Effectiveness of Carbon Ion Radiation Therapy for Skull Base Chordoma Utilizing Long-Term (10-Year) Outcome Data.

Sprave T, Verma V, Sterzing F, Bruckner T, Hees K, Land B, Jäkel O, Herfarth K, Debus J, Uhl M.

Anticancer Res. 2018 Aug;38(8):4853-4858. doi: 10.21873/anticanres.12797.

PMID:
30061259
24.

Trimodality therapy for esophageal cancer at high volume facilities is associated with improved postoperative outcomes and overall survival.

Haque W, Verma V, Butler EB, Teh BS.

Dis Esophagus. 2018 Jul 23. doi: 10.1093/dote/doy067. [Epub ahead of print]

PMID:
30052835
25.

Entropically driven controlled release of paclitaxel from poly(2-ethyl-2-oxazoline) coated maghemite nanostructures for magnetically guided cancer therapy.

Kumar N, Tyeb S, Manzar N, Behera L, Ateeq B, Verma V.

Soft Matter. 2018 Aug 21;14(31):6537-6553. doi: 10.1039/c8sm01220b. Epub 2018 Jul 27.

PMID:
30051119
26.

Exploration of Pyrrolobenzodiazepine (PBD)-Dimers Containing Disulfide-Based Prodrugs as Payloads for Antibody-Drug Conjugates.

Pei Z, Chen C, Chen J, Cruz-Chuh JD, Delarosa R, Deng Y, Fourie-O'Donohue A, Figueroa I, Guo J, Jin W, Khojasteh SC, Kozak KR, Latifi B, Lee J, Li G, Lin E, Liu L, Lu J, Martin S, Ng C, Nguyen T, Ohri R, Lewis Phillips G, Pillow TH, Rowntree RK, Stagg NJ, Stokoe D, Ulufatu S, Verma VA, Wai J, Wang J, Xu K, Xu Z, Yao H, Yu SF, Zhang D, Dragovich PS.

Mol Pharm. 2018 Sep 4;15(9):3979-3996. doi: 10.1021/acs.molpharmaceut.8b00431. Epub 2018 Aug 6.

PMID:
30040421
27.

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.

Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM.

Blood Adv. 2018 Jul 24;2(14):1765-1772. doi: 10.1182/bloodadvances.2018019414.

28.

Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer.

Haque W, Verma V, Polamraju P, Farach A, Butler EB, Teh BS.

Radiother Oncol. 2018 Jul 18. pii: S0167-8140(18)33395-4. doi: 10.1016/j.radonc.2018.07.008. [Epub ahead of print]

PMID:
30031630
29.

Neurodegenerative diseases: model organisms, pathology and autophagy.

Suresh SN, Verma V, Sateesh S, Clement JP, Manjithaya R.

J Genet. 2018 Jul;97(3):679-701.

30.

Spontaneous gall bladder perforation with ischaemic bowel disease: a rare cause of acute abdomen with pneumoperitoneum in elderly.

Wadhwani N, Meena OK, Verma V.

BMJ Case Rep. 2018 Jul 17;2018. pii: bcr-2018-224883. doi: 10.1136/bcr-2018-224883.

PMID:
30018034
31.

Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials.

Verma V, Cushman TR, Selek U, Tang C, Welsh JW.

Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1141-1148. doi: 10.1016/j.ijrobp.2018.04.054. Epub 2018 Apr 27.

PMID:
30012526
32.

Omission of chemotherapy for low-grade, luminal A N1 breast cancer: Patterns of care and clinical outcomes.

Haque W, Verma V, Hatch S, Klimberg VS, Butler EB, Teh BS.

Breast. 2018 Oct;41:67-73. doi: 10.1016/j.breast.2018.06.014. Epub 2018 Jul 2.

PMID:
30007270
33.

Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base.

Verma V, Kusi Appiah A, Lautenschlaeger T, Adeberg S, Simone CB 2nd, Lin C.

J Gastrointest Oncol. 2018 Jun;9(3):527-535. doi: 10.21037/jgo.2018.01.15.

34.

Utilization of intensity modulated radiation therapy for anal cancer in the United States.

Haque W, Verma V, Butler EB, Teh BS.

J Gastrointest Oncol. 2018 Jun;9(3):466-477. doi: 10.21037/jgo.2018.03.03.

35.

Environmental impact on the onset of hypertension-induced end-stage renal disease.

Anbarasu K, Verma VK, Beevi SS, Reddy VS.

Int J Environ Health Res. 2018 Oct;28(5):511-521. doi: 10.1080/09603123.2018.1491954. Epub 2018 Jul 10.

PMID:
29989454
36.

Radiation-induced acute toxicities after image-guided intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for patients with spinal metastases (IRON-1 trial) : First results of a randomized controlled trial.

Sprave T, Verma V, Förster R, Schlampp I, Bruckner T, Bostel T, Welte SE, Tonndorf-Martini E, El Shafie R, Nicolay NH, Debus J, Rief H.

Strahlenther Onkol. 2018 Jul 5. doi: 10.1007/s00066-018-1333-z. [Epub ahead of print]

PMID:
29978307
37.

Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM.

Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1468893. [Epub ahead of print] No abstract available.

PMID:
29963936
38.

Cardiac mortality in limited-stage small cell lung cancer.

Verma V, Fakhreddine MH, Haque W, Butler EB, Teh BS, Simone CB 2nd.

Radiother Oncol. 2018 Sep;128(3):492-497. doi: 10.1016/j.radonc.2018.06.011. Epub 2018 Jun 19.

PMID:
29934110
39.

Use of PET and Other Functional Imaging to Guide Target Delineation in Radiation Oncology.

Verma V, Choi JI, Sawant A, Gullapalli RP, Chen W, Alavi A, Simone CB 2nd.

Semin Radiat Oncol. 2018 Jun;28(3):171-177. doi: 10.1016/j.semradonc.2018.02.001. Review.

PMID:
29933876
40.

Data showing levels of interleukin-1β and nitric oxide in the plasma of uropathogenic E. coli infected UTI patients.

Verma V, Arora R, Dhanda RS, Gaind R, Yadav M.

Data Brief. 2018 May 18;19:526-529. doi: 10.1016/j.dib.2018.05.058. eCollection 2018 Aug.

41.

Use of Computer-Assisted Personal Interviewing and Information Management System in a Survey among HIV High-Risk Groups in India: Strengths, Weaknesses, Opportunities, and Threats Analysis.

Brahme R, Godbole S, Gangakhedkar R, Sachdeva KS, Verma V, Risbud A.

Indian J Community Med. 2018 Apr-Jun;43(2):107-112. doi: 10.4103/ijcm.IJCM_273_17.

42.

NOD is a plus end-directed motor that binds EB1 via a new microtubule tip localization sequence.

Ye AA, Verma V, Maresca TJ.

J Cell Biol. 2018 Sep 3;217(9):3007-3017. doi: 10.1083/jcb.201708109. Epub 2018 Jun 13.

PMID:
29899040
43.

Proton therapy for small cell lung cancer.

Verma V, Choi JI, Simone CB 2nd.

Transl Lung Cancer Res. 2018 Apr;7(2):134-140. doi: 10.21037/tlcr.2018.04.02. Review.

44.

Sclerosing Epithelioid Fibrosarcoma of the Coccyx: A Case Report and Review of Literature.

Popli A, Mahajan R, Rustagi T, Gupta S, Verma V, Gupta H.

Cureus. 2018 Apr 2;10(4):e2407. doi: 10.7759/cureus.2407.

45.

Comparison of proton therapy and intensity modulated photon radiotherapy for locally advanced non-small cell lung cancer: considerations for optimal trial design.

Cushman TR, Verma V, Rwigema JM.

J Thorac Dis. 2018 Apr;10(Suppl 9):S988-S990. doi: 10.21037/jtd.2018.04.59. No abstract available.

46.

Controversies in dose-escalation for locally advanced non-small cell lung cancer and the role of proton beam therapy.

Verma V, Chang JY.

J Thorac Dis. 2018 Apr;10(Suppl 9):S1124-S1126. doi: 10.21037/jtd.2018.03.155. No abstract available.

47.

Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy.

Sprave T, Verma V, Förster R, Schlampp I, Bruckner T, Bostel T, Welte SE, Tonndorf-Martini E, Nicolay NH, Debus J, Rief H.

Radiother Oncol. 2018 Aug;128(2):274-282. doi: 10.1016/j.radonc.2018.04.030. Epub 2018 May 26.

48.

Utilization of Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma in the United States.

Shaaban SG, Verma V, Choi JI, Shabason J, Sharma S, Glass E, Grover S, Badiyan SN, Simone CB 2nd.

Clin Lung Cancer. 2018 Sep;19(5):e685-e692. doi: 10.1016/j.cllc.2018.04.019. Epub 2018 May 5.

PMID:
29803576
49.

More robust gut immune responses induced by combining intranasal and sublingual routes for prime-boost immunization.

Hwang HS, Puth S, Tan W, Verma V, Jeong K, Lee SE, Rhee JH.

Hum Vaccin Immunother. 2018 May 21:1-9. doi: 10.1080/21645515.2018.1472185. [Epub ahead of print]

PMID:
29781755
50.

Utilization of neoadjuvant intensity-modulated radiation therapy and proton beam therapy for esophageal cancer in the United States.

Haque W, Verma V, Butler EB, Teh BS.

J Gastrointest Oncol. 2018 Apr;9(2):282-294. doi: 10.21037/jgo.2017.11.14.

Supplemental Content

Support Center